Clinical significance of extended-spectrum beta-lactamases.
about
Clinical management of infections caused by multidrug-resistant EnterobacteriaceaeThe role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae.CTX-M Enzymes: Origin and Diffusion.Why the extended-spectrum beta-lactamases SHV-2 and SHV-5 are "hypersusceptible" to mechanism-based inhibitorsRandomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coliRisk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli.Epidemiology of infections due to extended-spectrum Beta-lactamase-producing bacteria in a pediatric intensive care unit.Enumeration and characterization of antimicrobial-resistant Escherichia coli bacteria in effluent from municipal, hospital, and secondary treatment facility sourcesPrevalence and risk factors for extended spectrum Beta-lactamase-producing uropathogens in patients with urinary tract infection.Rapid, low-cost fluorescent assay of β-lactamase-derived antibiotic resistance and related antibiotic susceptibility.Emergence in Spain of a multidrug-resistant Enterobacter cloacae clinical isolate producing SFO-1 extended-spectrum beta-lactamaseExposure of Escherichia coli ATCC 12806 to sublethal concentrations of food-grade biocides influences its ability to form biofilm, resistance to antimicrobials, and ultrastructure.CTX-M-14 β-lactamase-producing Citrobacter freundii isolated in Venezuela.Extended-spectrum-beta-lactamase producing bacteria related urinary tract infection in renal transplant recipients and effect on allograft functionFosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.Extraintestinal Pathogenic Escherichia coli: A Combination of Virulence with Antibiotic ResistanceMolecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum β-lactamase-producing Escherichia coli causing bacteremia in a centralized Canadian regionIntestinal decolonization of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBL): a retrospective observational study in patients at risk for infection and a brief review of the literature.Epidemiology and Burden of Bloodstream Infections Caused by Extended-Spectrum Beta-Lactamase Producing Enterobacteriaceae in a Pediatric Hospital in Senegal.In vitro activities of 21 antimicrobial agents alone and in combination with aminoglycosides or fluoroquinolones against extended-spectrum-β-lactamase-producing Escherichia coli isolates causing bacteremiaESBL Detection: Comparison of a Commercially Available Chromogenic Test for Third Generation Cephalosporine Resistance and Automated Susceptibility Testing in EnterobactericeaeKlebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy.Epidemiologic and clinical impact of Acinetobacter baumannii colonization and infection: a reappraisal.Multidrug Resistant CTX-M-Producing Escherichia coli: A Growing Threat among HIV Patients in India.Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing EnterobacteriaceaeIn vitro Effectiveness of Commercial Bacteriophage Cocktails on Diverse Extended-Spectrum Beta-Lactamase Producing Escherichia coli Strains.ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.Clinical efficacy of β-lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrosCurrent management of bloodstream infections.Emergence and spread of antibiotic resistance following exposure to antibiotics.Detecting risk and predicting patient mortality in patients with extended-spectrum β-lactamase-producing Enterobacteriaceae bloodstream infections.Extraintestinal pathogenic Escherichia coli: an update on antimicrobial resistance, laboratory diagnosis and treatment.Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections.Treatment option for sepsis in children in the era of antibiotic resistance.Modifications of the C6-substituent of penicillin sulfones with the goal of improving inhibitor recognition and efficacy.The complex epidemiology of extended-spectrum β-lactamase-producing Enterobacteriaceae.Tackling antimicrobial resistance in lower urinary tract infections: treatment options.A comparison of blood stream infections with extended spectrum beta-lactamase-producing and non-producing Klebsiella pneumoniae in pediatric patients.Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae.
P2860
Q28246841-0B689C83-A960-45C5-996C-106ED9195B63Q30300020-01136693-3EEE-41C3-8D4C-2F3A2C0154E2Q30415141-3061894B-BA27-4EFE-A18C-75520BD7F268Q30491327-1AD37C2B-029C-4A77-84DB-8DB3F998FA38Q33776486-3454B51E-C17E-44D5-848A-D66F205FFDC8Q33827095-B7A9890F-1A80-4D47-B536-93042DB11D15Q33886817-EE4B2EDA-E0C1-4E97-93CC-49DCB8054662Q33983457-A78136F1-6966-4865-9292-93F5035FC49FQ34009487-9722D43F-757E-4224-9D83-853262737287Q34319946-FC25DB26-A265-4C62-BF68-BC8C2420D460Q34741562-5ED199E9-B3AB-46F2-B8FB-6764F3CB02A8Q35062393-1623FF67-CAF7-48F2-9640-D1DE155DB059Q35063662-C85E2076-D5ED-494C-AF2C-0CE2426957E1Q35122946-928A01C6-C6B2-4748-8917-99D7D6F8EE5DQ35278325-A3EF540E-DE3F-4D67-8C87-79B92E2B08ADQ35681590-20B5348F-F33F-4950-A6EE-8592AC0BA440Q35689028-586084C2-4971-433B-92DE-4FF6DC52CFF7Q35825390-2E9BB328-7DB0-4E9F-AE60-0C776440B61EQ35921039-3BD62550-3FCC-4459-94E8-A1052F598125Q35961012-59CBABD5-92AA-471A-A203-841836E5456AQ36095794-211834F2-00AE-469C-9103-978D700F4C31Q36150730-CDFB7731-6915-4EE9-9F6F-85751DE1701AQ36150941-0DF68D80-1899-4FF8-A607-B1BAEC5B37C3Q36792780-87F1C810-166C-4359-9EF5-4C8F4B53FBE9Q36901488-19AFA355-9076-4985-83CA-C0D5B99D14A5Q37023191-DF72C03A-06C5-4FF6-A475-DA721E4F9C2FQ37389468-A3C64B0E-4256-42E8-87FB-7C93C637D935Q37392705-677C4FD8-6F38-4208-AB62-1CA7174682B7Q37612207-D17066DC-A6C7-4951-A844-776A1EE009B0Q37768418-480C860B-08A6-4A14-93CA-02AF6C219261Q37896674-A466282B-8589-43A6-AC8F-076FF94A5D19Q38048860-1F813F6F-A6D9-4E0B-B684-82A4E3E0B4DBQ38063968-4F6D0891-5D7E-47B8-AA13-9077E4500052Q38145311-7F8ADE44-7384-4FE8-9AE2-04EE6953EBBFQ38246118-5CAEC7BC-2802-4E70-8784-E5B7725B4A47Q38314617-A945A912-479A-4515-86F2-D8C4C1C77C85Q38497797-93D24096-5F52-40AB-8ADB-E48F95E7D9F6Q38833839-944FFB9A-495F-49E4-A250-9B4681EEB8CFQ40050797-593CE1D3-F31B-425B-B892-C984FAEDC9F6Q40381772-B45F9E8C-5DF7-41DC-B515-930E5D3F1CFA
P2860
Clinical significance of extended-spectrum beta-lactamases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical significance of extended-spectrum beta-lactamases.
@en
Clinical significance of extended-spectrum beta-lactamases.
@nl
type
label
Clinical significance of extended-spectrum beta-lactamases.
@en
Clinical significance of extended-spectrum beta-lactamases.
@nl
prefLabel
Clinical significance of extended-spectrum beta-lactamases.
@en
Clinical significance of extended-spectrum beta-lactamases.
@nl
P2860
P356
P1476
Clinical significance of extended-spectrum beta-lactamases
@en
P2093
Alvaro Pascual
P2860
P304
P356
10.1586/14787210.6.5.671
P577
2008-10-01T00:00:00Z